Research on what, in whom, measured how

TL;DR

• "There's research on it" is three claims wearing one coat - research on what, in whom, and measured how.
• The failure mode is compression, not fabrication. Each retelling sheds one qualifier until the summary is a claim nobody actually made.
• A fragment, a modified version or a precursor is not the same substance - and route matters: topical, oral and injected are three different exposures.
• Correction is not enhancement. A trial in people with a diagnosed deficiency answers a different question from one about someone already within a normal range.
• The endpoint ladder runs biomarker → surrogate endpoint → clinical outcome - and movement on a lower rung does not guarantee movement on a higher one.
• When the three questions can't be answered because the claim traces to a summary of a summary, that is itself the finding.

Educational content, not medical advice. The framework names no compound; the closing section points to compound pages that apply it. No doses or protocols appear. Decisions about any therapy belong with a qualified clinician.

---

You have almost certainly had this experience. Someone tells you there is research behind something. You go looking, and the research exists - a real paper, real authors, a real journal. And yet, an hour later, you are less sure than when you started, and you cannot articulate why.

Here is why. "There's research on it" compresses three separate claims into one sentence, and the compression is where the meaning leaks out:

1. Research on what - the exact substance, or something adjacent to it?
2. Research in whom - humans, and which humans?
3. Measured how - what did the study actually record, and is that the thing you care about?

Each question has an honest answer. The answers are usually written down. They are almost never in the headline, and they are almost never in the sentence someone says to you. Learning to ask for all three is the single highest-leverage reading skill in this entire field, and it takes about four seconds once you have the habit.

"There's research on it" is not one claim, it's three

Consider what has to be true for that sentence to mean what a listener naturally hears it meaning: this substance, given to people like me, produced the outcome I want.

That is a specific and demanding claim. It requires the study to have used the same substance, in a relevant population, and to have measured the outcome under discussion. A study that satisfies one of those three is still, correctly, "research on it." A study that satisfies all three is a different kind of object entirely.

The failure mode is not fabrication. It is compression - a real finding described accurately at each step, each step shedding one qualifier, until the summary is a claim nobody made. The sentence at the end of that chain is usually defensible if you interrogate it word by word, and misleading if you simply hear it.

So the discipline is not scepticism. Scepticism, applied indiscriminately, is just a different way of being wrong. The discipline is asking three specific questions, and noticing when they cannot be answered.

Research on what - the substance, the formulation, or the category

The first question sounds trivial and is not.

Was it the same substance? Compounds have relatives. A fragment of a larger molecule is not the larger molecule. A modified version with a chemical group attached to extend its lifespan in the body is not the unmodified version. A precursor that the body converts into something else is not the something else. All of these routinely get discussed under one name, and in each case the research on one is being quietly lent to the other.

Was it the same formulation and route? How a substance is delivered changes what reaches the tissue in question, and sometimes changes it by orders of magnitude. Something applied to the skin, something swallowed, and something injected are three different exposures. Research conducted with one route does not automatically describe another, and this is one of the most common silent substitutions in health content.

Was it the substance at all, or the category? "Peptides have been shown to…" is a sentence about a category so broad it includes insulin and includes things with essentially no human data. Categories do not have evidence. Specific substances, in specific forms, studied in specific ways, have evidence. When a claim is made at the level of a category, the useful response is not disagreement - it is a request for the specific.

And was it a study of the substance, or of a mechanism the substance is thought to touch? Mechanism work - what happens to cells in a dish, what a receptor does when it is activated - is genuinely valuable and genuinely not the same category of evidence. It tells you why something might work. That is a reason to run a trial. It is not a result.

In whom - species, health status, and how narrow the enrolled group was

The second question is where the largest leaps hide, and it has four parts.

Species. A great deal of early research is done in cells and in animals, for good and ethical reasons. It is also the point at which the most confident-sounding claims are generated, because animal models are designed to produce clean signals. A rodent, a rabbit and a human differ in metabolism, in dose scaling, in lifespan, in immune function and in the anatomy of whatever is being studied. Findings sometimes transfer. Historically, most do not - the attrition rate between promising animal work and successful human trials is the central fact of drug development, and it is not a small effect.

Health status. A study in people with a diagnosed deficiency, a specific disease, or a surgical injury is answering a question about correction. It is not answering a question about enhancement in someone who is already within a normal range. These are different questions with different expected answers, and results from the first are routinely presented as answers to the second. Restoring something that is missing and adding to something that is already sufficient are not the same intervention.

Age and sex. Populations enrolled in trials are frequently narrower than the populations that later read about them. Hormonal environment, body composition, kidney and liver function and baseline risk all differ across age and sex, and any of them can change a result's direction or size.

How narrow was the enrolled group? Trials have inclusion and exclusion criteria, and they are often long. Participants may have been screened for a specific range of body weight, excluded for common medications, excluded for common comorbidities. The resulting group can be quite unlike the average person who will eventually read the headline. This is not a flaw - narrow enrolment is what makes a signal detectable. It is simply a limit on who the answer describes, and that limit almost never survives into the summary.

Measured how - what an endpoint is, and why it decides the headline

The third question is the one almost nobody asks, and it is the most powerful of the three.

An endpoint is the specific thing a study recorded and analysed. It is chosen before the study runs, it determines how the study is designed and how large it needs to be, and it is the thing the result is actually about. Everything else the study mentions is secondary - interesting, hypothesis-generating, and not what was tested.

The reason this matters so much is that the endpoint decides the headline. A study that measured one thing will produce a headline about that thing, and then the headline will be read as if it were about something bigger. Not because anyone lied, but because the endpoint disappeared somewhere between the paper and the summary.

Three specific things to look for:

• Was the endpoint pre-specified, or found afterwards? A result that was the study's stated question carries far more weight than one noticed while looking through the data afterwards. The second kind is a reason to run another study, not a finding.
• Was it measured, or reported? Something recorded by an instrument and something recorded on a questionnaire are both legitimate data and are not equivalent evidence.
• Compared to what? A change from a starting point is a different claim from a change relative to a control group. Almost everything improves somewhat against its own baseline, for reasons that have nothing to do with the intervention. The comparison is the whole experiment. Why that comparison is so hard to construct when the condition improves on its own anyway is worked through in why injury studies are hard to read.

The endpoint ladder, defined

Endpoints come in tiers, and naming the tiers makes a large amount of health content suddenly readable. The definitions below are exactly that - definitions. No substance is being placed on this ladder here, deliberately, for a reason given at the end.

Two properties of this ladder do the real work.

The further up you go, the more the endpoint matters and the harder it is to measure. Clinical outcomes need more people, more time and more money, because the events being counted are often uncommon. That is the entire reason surrogates exist.

Movement on a lower rung does not guarantee movement on a higher one. This is the part that is genuinely counterintuitive, and it is not hedging. Medicine has a documented history of interventions that moved a surrogate convincingly and then failed - or caused harm - at the outcome that mattered. It has happened in cardiology and in metabolic medicine, and it is why regulators treat surrogate-based evidence as provisional rather than final. If you want the formal version of that caution, what FDA accelerated approval actually means covers the framework built specifically to handle it.

The ladder is not a scoring system. It is a question: which rung was measured, and which rung is the claim standing on?

Where the three questions give three different answers

In practice the questions rarely fail together. They fail one at a time, and the sentence survives because the other two hold.

• Right substance, right endpoint, wrong species - a clean result on a meaningful outcome, in an animal.
• Right substance, human participants, low rung - a real human study that measured a marker, described as though it had measured an outcome.
• Human participants, meaningful outcome, adjacent substance - a good trial of something related, lent to something else that shares a name.
• All three defensible, but the enrolled group was people with a specific deficiency, and the claim is being made to people without one.

Each of these produces a summary sentence that is difficult to attack head-on, because nothing in it is false. What is missing is a qualifier. The three questions are how you find out which one.

And there is a fifth pattern worth naming, because it is the most common of all: the questions cannot be answered, because the source of the claim is a summary of a summary. When a claim cannot be traced to a study whose substance, population and endpoint can be checked, that is itself the finding. It does not mean the claim is false. It means nobody in the chain has demonstrated that it is true.

What to do with this: the questions to bring to a clinician

Here is where this page stops, and the stop is deliberate.

Being able to see these three questions does not put you in a position to judge whether a therapy is right for you. That judgement needs things this framework cannot supply: your own history, your own medications and interactions, your own examination and laboratory results, and a clinician's experience of how this evidence behaves in practice across many people rather than in one paper. Reading methods well is a defence against being misled. It is not a substitute for assessment, and treating it as one is simply a more sophisticated way of self-prescribing.

What the framework is genuinely good for is making a consultation better. It turns a vague question into a specific one, and specific questions get specific answers. Worth bringing:

• What is the evidence for this in people like me - same age, same sex, same health status?
• What did the main studies actually measure, and is that the outcome I am asking about?
• Is this a case where a marker moved, or where something happened to people?
• What would you expect to see, in me, and how would we know if it were not working?
• What is the honest strength of this evidence - strong, promising, or early?

A clinician who welcomes those questions is the one you want. A source that finds them irritating has told you something useful too.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial.

Frequently asked questions

How can I tell what a study actually measured? Look for the endpoint - the specific thing the study recorded and analysed, chosen before it began. It is usually stated in the abstract's methods sentence and in the results, and it is usually absent from the headline. Then ask whether the claim being made sits on that endpoint or on a bigger one.

Does "there's research on it" mean it works? No, and it is not meant to. It means a study exists. Whether it supports a given claim depends on what was studied, who it was studied in, and what was measured. All three can be answered honestly and still not add up to the claim being made.

Is animal research useless, then? Not at all - it is how nearly everything begins, and it is where mechanisms are established. It is simply not evidence that something works in people. The correct reading of a strong animal result is "this is worth testing in humans," which is a real and valuable thing for a study to establish.

What is a surrogate endpoint? A measurement believed to stand in for an outcome people care about - a scan or a laboratory value used in place of waiting to see whether an event occurs. Surrogates make trials faster and cheaper. They are also the point at which evidence most often turns out to be weaker than it looked, because a surrogate can move without the outcome following.

If I can read studies, do I still need a doctor? Yes - the two skills answer different questions. Reading methods tells you what a piece of evidence is worth in general. It cannot tell you what is appropriate for your history, your medications, your baseline results or your risk profile. That assessment is a clinical judgement, and no amount of reading substitutes for it.

Putting the ladder to work

The framework above is a reading tool, and it is most useful when you are weighing something specific. Each Vivre Labs compound page applies the same discipline to one compound, setting out where its evidence sits and its regulatory status: for example BPC-157, an investigational peptide whose evidence is mostly animal research, and semaglutide, an approved medicine with large outcome trials behind it. Reading the two side by side shows the ladder in action. If you want a clinician to apply it to your own situation, start with a baseline biomarker panel and a conversation with your own doctor.

Related reading

• What peptides actually are · What 565 studies actually found about six popular peptides · What FDA accelerated approval means · What adverse event reports do and don't tell you · Peptide side effects, honestly · Biomarker monitoring in peptide therapy · Optimal versus normal lab ranges
• Part of The Complete Guide to Peptides

---

Educational content, not medical advice. The endpoint ladder is a reading tool; this article does not rank any compound on it, and the compound pages linked above are where each one's evidence is set out. Nothing here is a basis for starting, stopping or changing any therapy; that decision belongs with a qualified clinician who has assessed you. Claims for the Malaysian market are subject to MAB requirements.

References

• Definitions of biomarker, surrogate endpoint and clinical outcome follow the FDA–NIH BEST (Biomarkers, EndpointS, and other Tools) Resource, Silver Spring (MD) and Bethesda (MD), continuously updated. · On the historical failure of surrogate endpoints to predict clinical outcomes: Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605–613. · Prasad V, et al. The strength of association between surrogate end points and survival in oncology. JAMA Intern Med. 2015;175(8):1389–1398. · On attrition between preclinical and clinical evidence: Perel P, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334:197. · Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296(14):1731–1732. · On pre-specification and outcome reporting: Chan AW, et al. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA. 2004;291(20):2457–2465. · On restrictive eligibility criteria and generalisability: Van Spall HGC, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. JAMA. 2007;297(11):1233–1240.